Last reviewed · How we verify

NCT06204536: TREAAT2+

Treatment Planning for ABA Employing Auxiliary Tools V2+ (TREAAT2+)

Not yet recruiting Phase 1, PHASE2 Last updated 22 November 2024
What this trial tests

Phase 1, PHASE2 trial testing Tech-enabled ABA treatment planning in Autism Spectrum Disorder in 20 participants. Not yet recruiting.

Timeline
1 July 2025
Primary endpoint
30 June 2027
30 June 2027

Quick facts

Lead sponsorMontera Health Texas LLC
PhasePhase 1, PHASE2
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposehealth services research
Enrollment20
Start date1 July 2025
Primary completion30 June 2027
Estimated completion30 June 2027

Drugs / interventions tested

Conditions studied

Sponsor

Montera Health Texas LLC

Who can join

Eligibility, any sex, with Autism Spectrum Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Technology enhancement in Applied Behavior Analysis (ABA) treatment planning may increase confidence, efficiency, consistency, and satisfaction for Board Certified Behavior Analysts (BCBAs) which, in turn, can provide for better clinical outcomes for patients on the autism spectrum. To this end, the investigators will examine the use of \>3 technology-based tools that will be implemented in the BCBAs' clinical workflow to aid with treatment planning. The study will initially involve two aims that are non-interventional (these processes will occur in the background and will have no impact on any cohorts), followed by an interventional aim that includes two arms (i.e., two BCBA cohorts). BCBAs within both arms will observe and practice the standard of care for ABA, and thus patient care will not be impacted. The outcome measures are primarily focused on the BCBAs as follows: Arm 1: An experimental group (BCBA Tech cohort) will receive the full tech package (TREAAT2+) from the start. Arm 2: The control group (BCBA non-Tech cohort) will not have access to any tools from the tech package for the first 6 months. In the subsequent 18 months, they will receive one tool every 6 months until gaining access to the entire tech package.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Autism Spectrum Disorder

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06204536.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing